Personalized radiation treatment for HPV-related throat cancer

A personalized approach using hypoxia resolution to guide curative-intent radiation dose reduction to 30 Gy: A novel de-escalation paradigm for HPV-associated oropharynx cancers

NIH-funded research Sloan-Kettering Inst Can Research · NIH-11167125

This study is looking at a new way to give less radiation to patients with HPV-related throat cancer, using special scans to see how well they respond to treatment, so they can safely get a lower dose without losing effectiveness and hopefully experience fewer side effects.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionSloan-Kettering Inst Can Research NIH-funded
Lab location1 site (New York, United States)
Project IDNIH-11167125 on NIH RePORTER

What this research studies

This research investigates a personalized approach to reduce radiation doses for patients with HPV-associated oropharyngeal cancers. By using a specific imaging biomarker, the study aims to determine whether patients can safely receive a lower radiation dose of 30 Gy instead of the standard 70 Gy without compromising treatment effectiveness. The approach involves assessing patients' responses to initial chemotherapy and using PET scans to guide treatment decisions. This method seeks to minimize side effects while maintaining the efficacy of cancer treatment.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients with early-stage or advanced-stage HPV-positive oropharyngeal cancers who are undergoing chemoradiation therapy.

Not a fit: Patients with non-HPV-related throat cancers or those who do not meet the specific criteria for treatment de-escalation may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to safer and more effective radiation treatments for patients with HPV-related throat cancer.

How similar studies have performed: Previous studies have shown promising results with similar personalized treatment approaches, indicating potential for success in this novel application.

Where this research is happening

New York, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.